Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183843 | 0.78 | LOXL2 (0.48) | HSD17B10LOXL2CYP1A2CYP2D6 | |
| SCHEMBL1302121 | 0.78 | TDP1 (0.46) | SMN1; SMN2LMNAALDH1A1HSD17B10LOXL2 | |
| SCHEMBL2141447 | 0.77 | LOXL2 (0.41) | SMN1; SMN2LMNAALDH1A1GAAHSD17B10 | |
| SCHEMBL2704300 | 0.77 | ALDH1A1 (0.44) | SMN1; SMN2LMNAALDH1A1GAAHSD17B10 | |
| SCHEMBL348707 | 0.77 | CYP1A2 (0.64) | ALDH1A1MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27353 | 0.76 | CA2 (0.48) | ALDH1A1GAAHSD17B10MAPTCYP3A4 | |
| SCHEMBL6354330 | 0.74 | ALDH1A1 (0.45) | SMN1; SMN2LMNAALDH1A1GAAHTT | |
| SCHEMBL5254440 | 0.74 | HRH1 (0.48) | SMN1; SMN2LMNAALDH1A1LOXL2HTT | |
| SCHEMBL5221613 | 0.73 | ESR1 (0.44) | ALDH1A1GAAHSD17B10MAPTMEN1 | |
| SCHEMBL1486307 | 0.73 | LMNA (0.47) | LMNAALDH1A1LOXL2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | claimed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | claimed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | claimed |
| WO-2018049214-A9 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-10-18 | — | — | WO | claimed |
| WO-2018049214-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | claimed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | claimed |
| CN-101341129-B | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2011-12-14 | — | — | CN | claimed |
| US-7919511-B2 | Aminopyridines, e.g., 6-(2-cyanophenyl)-4-{[2-(3-fluorophenyl)ethyl]amino}(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | claimed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | claimed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | claimed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | claimed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| WO-1992017176-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1992-10-15 | — | — | WO | claimed |
| US-5151438-A | Enzyme inhibitors for treatment of aids | ABBOTT LABORATORIES (US) | 1992-09-29 | — | — | US | claimed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SMN1; SMN2 3405/4885LMNA 2520/4885ALDH1A1 2205/4885 |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SMN1; SMN2 3405/4885LMNA 2520/4885ALDH1A1 2205/4885 |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SMN1; SMN2 3405/4885LMNA 2520/4885ALDH1A1 2205/4885 |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SMN1; SMN2 3405/4885LMNA 2520/4885ALDH1A1 2205/4885 |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | SMN1; SMN2 3405/4885LMNA 2520/4885ALDH1A1 2205/4885 |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | SMN1; SMN2 3405/4885LMNA 2520/4885ALDH1A1 2205/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | SMN1; SMN2 3686/4885LMNA 2874/4885ALDH1A1 1152/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | SMN1; SMN2 3648/4885LMNA 3333/4885ALDH1A1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.